
Edwards Lifesciences (EW) Stock
Heart valve leader for critical care monitoring. Here's the price, business snapshot, and what's worth knowing about Edwards Lifesciences in November 2026.
Edwards Lifesciences Corporation (EW) is a medical-technology company focused on heart valves and critical-care monitoring. It is best known for the Sapien transcatheter aortic valve replacement (TAVR) system and a broad range of surgical valves and haemodynamic monitoring products. Investors typically monitor Edwards for its leadership in structural heart therapies, clinical-driven innovation, and exposure to an ageing population that boosts demand for valve procedures. Revenue growth is linked to procedure volumes, reimbursement environments and the success of clinical trials and new indications. The company invests in R&D and selective acquisitions to extend its portfolio and geographic reach. Key risks include competition, regulatory and reimbursement shifts, and sensitivity to elective-procedure cycles. This is general educational information only and not personalised financial advice; values can rise or fall and past performance is not a reliable guide. Consider your own circumstances or consult a financial adviser before making investment decisions.
Why It’s Moving

Edwards Lifesciences Shares Climb on Q3 Beat and Strong Clinical Trial Data
- Q3 sales grew 10.5% to $1.72 billion, with adjusted EPS rising 19% year-over-year to $0.80, prompting an increase in 2026 guidance.
- The CLASP II TR trial demonstrated superiority of the PASCAL system over medical therapy alone, showing significant reduction in tricuspid regurgitation and improved health status sustained through one year.
- Results from the PROGRESS trial confirmed that TAVR is superior to clinical surveillance for moderate aortic stenosis patients with at-risk features, marking a potential turning point in patient management.

Edwards Lifesciences Shares Climb on Q3 Beat and Strong Clinical Trial Data
- Q3 sales grew 10.5% to $1.72 billion, with adjusted EPS rising 19% year-over-year to $0.80, prompting an increase in 2026 guidance.
- The CLASP II TR trial demonstrated superiority of the PASCAL system over medical therapy alone, showing significant reduction in tricuspid regurgitation and improved health status sustained through one year.
- Results from the PROGRESS trial confirmed that TAVR is superior to clinical surveillance for moderate aortic stenosis patients with at-risk features, marking a potential turning point in patient management.
Sixth Month Growth Performance
When is the next earnings date for EDWARDS LIFESCIENCES CORP (EW)?
The next confirmed earnings date for EW is November 4, 2026, scheduled to release after market close. This report will cover the company's third quarter of fiscal year 2026 results. Investors should note that this timing aligns with the historical pattern of reporting approximately three months after the previous July announcement.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Edwards Lifesciences' stock, expecting it to reach a higher price soon.
Financial Health
Edwards Lifesciences is performing well with strong revenue and profitability, indicating solid financial health.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Leader in TAVR
Edwards holds a strong position in transcatheter aortic valve replacement; adoption and expanded indications can support growth, though procedure volumes can fluctuate.
Clinical-driven innovation
Ongoing trials and new device launches are central to long-term prospects, but regulatory outcomes and trial timing can influence performance.
Demographics & reach
An ageing global population and geographic expansion present opportunities, while reimbursement and local regulation remain important considerations.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.